Newish Biotech starts third NWRD09 trial, this time in anal HPV16
The Phase 1 safety study extends a therapeutic HPV16 program already running in two other anatomic sites, in a field where most competing assets target head and neck cancer, not persistent infection.
Executive Summary
- Newish Biotech opened a Phase 1 open-label safety study of NWRD09 in patients with HPV16 infection that has persisted in the anal region, its third registered trial of the same drug in HPV16-related indications.
- The filing extends a program already testing NWRD09 in cervical and general female HPV16 persistence, suggesting the sponsor is probing the same mechanism across anatomic sites rather than betting on a single population.
- Most other clinical programs against HPV16 target head and neck cancer using therapeutic vaccines or cell therapies, leaving persistent infection, the indication NWRD09 is testing, comparatively less contested.
- The trial is a safety-first, small-cohort study whose primary purpose is establishing tolerability, not a decision-grade efficacy readout, and its early completion timeline sets when the next signal from this program could arrive.
The new study
The trial, filed on July 17, 2026, will enroll an anticipated 10 participants aged 18 to 60 whose anal HPV DNA genotyping has shown persistent HPV16 positivity for at least 12 months, with low-grade lesions, inflammation, or no histopathological abnormality at baseline. It is open-label, non-randomized, and split across two arms, with enrollment starting July 20, 2026. The primary endpoint is the incidence and severity of local and systemic adverse events over 28 weeks, graded by NCI CTCAE version 6.0 criteria, making this fundamentally a tolerability study. NCT07710664A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal RegionNCT07710664
Secondary measures
Beyond safety, the protocol tracks cellular immune response by interferon-gamma ELISPOT assay at baseline and weeks 6, 16, and 28, along with virologic clearance of HPV16 at weeks 16 and 28. A separate secondary measure looks at histopathological regression to no lesions at week 28 among participants who start with low-grade anal intraepithelial neoplasia. Those clearance and regression measures, not the primary safety endpoint, are what would signal whether NWRD09 is doing anything beyond being tolerated. The trial's primary completion date is set for December 30, 2026, with full study completion targeted for June 30, 2027. NCT07710664A Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal RegionNCT07710664
A multi-site program
This is not NWRD09's first HPV16 trial. Newish Biotech also has a Phase 1/2 study evaluating the drug in female participants with persistent HPV16 infection, not yet recruiting, and a separate trial testing it against persistent cervical HPV16 infection that is currently recruiting. Across all three, the sponsor is testing the same drug against HPV16 persistence in different anatomic compartments (cervical, general female, and now anal) before any of the three has posted data. That parallel-site design is the operational signal in this filing: it reads as a program mapping where NWRD09 works across tissue types rather than a single confirmatory bet.
The competitive field
The HPV16 clinical landscape is weighted toward head and neck squamous cell carcinoma rather than persistent infection. PDS Biotechnology Corp.'s PDS0101 is in a Phase 3 trial combined with pembrolizumab in HPV16-positive recurrent or metastatic head and neck cancer, and BioNTech SE's BNT113 is in Phase 3 for the same tumor type, both testing overall survival or treatment-emergent adverse events as primary measures. Closer to NWRD09's own setting, Nykode Therapeutics ASA's VB10.16 and BlueSky Immunotherapies GmbH's FluBHPVE6E7 immunotherapy are Phase 1/2 programs targeting HPV16 E6 and E6/E7 antigens, but both are also positioned in oropharyngeal or head and neck cancer rather than asymptomatic persistent infection. NWRD09's own target and mechanism class are not established in the trial record, so no direct target-matched comparator can be identified; the nearest comparable program remains Newish Biotech's own earlier NWRD09 trial in the same indication family. Against a field concentrated on established cancer rather than pre-cancerous persistence, a signal that NWRD09 clears HPV16 or regresses low-grade lesions before disease progression would distinguish this program from mechanisms designed to treat cancer that has already developed.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.